![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
North America Ocular Drug Delivery Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (Implantable Ocular Drug Delivery Systems, Particulate Drug Delivery Systems, Nano-Particle Drug Delivery System, and Others), Formulation Type (Liposomes and Nanoparticles, Solution, Emulsion, Suspension, and Ointment), Disease Type (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Macular Degeneration, Cataract, Diabetic Macular Edema, and Others), and End User (Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers)
Market Introduction
The North America ocular drug delivery market has been segmented into the US, Canada, and Mexico. The US holds the largest share of the North America ocular drug delivery market. In North America, the US holds a significant share of the ocular drug delivery market. The growth of the market in the US is primarily driven by product awareness and the increasing prevalence of eye diseases. Further, the aging population in the US is likely to increase the incidence of eye diseases, which will eventually drive the adoption of ocular drug delivery products in the country. For instance, as per the Population Reference Bureau 2019, the number of individuals in the US aged 65 and older is estimated to double from 52 million in 2018 to around 95 million by 2060, and the 65 and more age group’s share of the total population will increase from 16% to 23%. This aged population is highly vulnerable to eye conditions. For instance, as per the American Academy of Ophthalmology 2019 study, an estimated 7.32 million people aged 70-75 are affected by primary open-angle glaucoma (POAG) by 2050 in the US.
Amidst the COVID-19 crisis, the healthcare institutions have witnessed decrees in inpatient visits to clinics to prevent the spread of the COVID-19 in the first and second quarters of 2020. As per the recent study by CDC, the number of medical emergency department (ED) visits has declined 42% during the early COVID-19. As a result, the number of elective eye procedures performed per week in hospitals and clinics has decreased over time. According to an article in Ophthalmology Times, elective procedures have decreased in countries such as the United States. The number of patient visits to examination facilities has reduced by 15%. During the COVID-19 pandemic, ophthalmology lost a considerable share of patient volume; the volume of ophthalmic practice is predicted to have decreased by 81%, owing to a decline in patients seeking care for glaucoma and cataracts surgery.
![](https://www.theinsightpartners.com//assets/rdimages/25479-img1.png)
Get more information on this report :
Market Overview and Dynamics
The ocular drug delivery market in North America is expected to grow US$ 10,622.77 million by 2028 from US$ 6,286.54 million in 2021. The market is estimated to grow at a CAGR of 7.8% from 2021 to 2028. Several players operating in the ocular drug delivery market are developing and launching innovative products. The strategy of development and launch of new products helps companies to cater to a broad customer base. For instance, in June 2020, Senju Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced the launch of a new combination ophthalmic solution, AILAMIDE Combination Ophthalmic Suspension, for the treatment of glaucoma and ocular hypertension. Similarly, in October 2019, Sun Pharmaceutical Industries launched the ophthalmic solution Cequa in the US, which is used to treat dry-eye disease. Additionally, in May 2019, Menicon Co., Ltd launched Menicon Bloom Myopia Control Management System. Menicon Bloom Night therapy includes the overnight wearing of a specifically designed reverse geometry orthokeratology contact lens—manufactured in hyper oxygen-permeable Menicon Z rigid material that guarantees ideal corneal oxygenation for comfortable contact lens wear. Additionally, in January 2019, Ocular Therapeutix launched Dextenza (dexamethasone ophthalmic insert) 0.4 mg in the US to treat ocular inflammation and pain following ophthalmic surgery. Dextenza received FDA approval in November 2018 for the treatment of ocular pain following ophthalmic surgery. Such developments and launches of new products are emerging as a key trend in the ocular drug delivery market.
Key Market Segments
North America ocular drug delivery market is segmented based on technology, formulation type, disease type, end user. Based on technology, implantable ocular drug delivery systems segment accounted for the highest share in 2021. Based on formulation type, solution segment accounted for the highest share in 2021. Based on disease type, cataract segment accounted for the highest share in 2021. Based on end user hospitals segment accounted for the highest share in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on ocular drug delivery market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AbbVie Inc.; Bausch Health Companies Inc.; Novartis AG; Clearside Biomedical, Inc.; Ocular Therapeutix, Inc.; Envisia Therapeutics; Alimera Sciences, Inc.; EYEGATE PHARMACEUTICALS, INC. among others.
Reasons to buy report
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America ocular drug delivery market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in North America ocular drug delivery market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the ocular drug delivery market as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
North America Ocular Drug Delivery Market Segmentation
North America Ocular Drug Delivery Market – By Technology
- Implantable Ocular Drug Delivery Systems
- Particulate Drug Delivery Systems
- Nano-Particle Drug Delivery System
- Others
North America Ocular Drug Delivery Market – By Formulation Type
- Solution
- Ointment
- Suspension
- Emulsion
- Liposomes and Nanoparticles
North America Ocular Drug Delivery Market – By Disease type
- Cataract
- Dry Eye Syndrome
- Macular Degeneration
- Glaucoma
- Diabetic Retinopathy
- Diabetic Macular Edema
- Others
North America Ocular Drug Delivery Market – By End User
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers
North America Ocular Drug Delivery Market – By Country
- US
- Canada
- Mexico
North America Ocular Drug Delivery Market – Companies Mentioned
- AbbVie Inc.
- Bausch Health Companies Inc.
- Novartis AG
- Clearside Biomedical, Inc
- Ocular Therapeutix, Inc.
- Envisia Therapeutics
- Alimera Sciences, Inc.
- EYEGATE PHARMACEUTICALS, INC
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Ocular Drug Delivery Market – By Technology
1.3.2 North America Ocular Drug Delivery Market – By Formulation Type
1.3.3 North America Ocular Drug Delivery Market – By Disease Type
1.3.4 North America Ocular Drug Delivery Market – By End User
1.3.5 North America Ocular Drug Delivery Market – By Country
2. North America Ocular Drug Delivery Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Ocular Drug Delivery – Market Landscape
4.1 Overview
4.2 Expert Opinions
5. North America Ocular Drug Delivery Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Elevating Prevalence of Eye Disorders
5.2 Market Restraints
5.2.1 Limitations Associated with Ocular Drug Delivery
5.3 Market Opportunities
5.3.1 Expansion Awareness About Vision Care
5.4 Future Trends
5.4.1 Thriving of Innovative Products
5.5 Impact analysis
6. North America Ocular Drug Delivery – Market Analysis
6.1 North America Ocular Drug Delivery Market Revenue Forecast and Analysis
7. North America Ocular Drug Delivery Market Analysis – By Technology
7.1 Overview
7.2 North America Ocular Drug Delivery Market Share by Technology 2021 & 2028 (%)
7.3 Implantable Ocular Drug Delivery Systems
7.3.1 Overview
7.3.2 Implantable Ocular Drug Delivery Systems Market Revenue and Forecast to 2028 (US$ Million)
7.4 Particulate Drug Delivery Systems
7.4.1 Overview
7.4.2 Particulate Drug Delivery Systems Market Revenue and Forecast to 2028 (US$ Million)
7.5 Nano-Particle Drug Delivery System
7.5.1 Overview
7.5.2 Nano-Particle Drug Delivery System Market Revenue and Forecast to 2028 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)
8. North America Ocular Drug Delivery Market Analysis – By Formulation Type
8.1 Overview
8.1.1 North America Ocular Drug Delivery Market, By Formulation Type 2021 & 2028 (%)
8.2 Liposomes and Nanoparticles Market
8.2.1 Overview
8.2.2 Liposomes and Nanoparticles Market Revenue and Forecasts to 2028 (US$ Million)
8.3 Solution
8.3.1 Overview
8.3.2 Solution Market Revenue and Forecasts to 2028 (US$ Million)
8.4 Emulsion
8.4.1 Overview
8.4.2 Emulsion Market Revenue and Forecasts to 2028 (US$ Million)
8.5 Suspension
8.5.1 Overview
8.5.2 Suspension Market Revenue and Forecasts to 2028 (US$ Million)
8.6 Ointment
8.6.1 Overview
8.6.2 Ointment Market Revenue and Forecasts to 2028 (US$ Million)
9. North America Ocular Drug Delivery Market Analysis – By Disease Type
9.1 Overview
9.2 North America Ocular Drug Delivery Market Share by Disease Type 2021 & 2028 (%)
9.3 Cataract
9.3.1 Overview
9.3.2 Cataract Market Revenue and Forecast to 2028 (US$ Million)
9.4 Dry Eye Syndrome
9.4.1 Overview
9.4.2 Dry Eye Syndrome Market Revenue and Forecast to 2028 (US$ Million)
9.5 Macular Degeneration
9.5.1 Overview
9.5.2 Macular Degeneration Market Revenue and Forecast to 2028 (US$ Million)
9.6 Glaucoma
9.6.1 Overview
9.6.2 Glaucoma Market Revenue and Forecast to 2028 (US$ Million)
9.7 Diabetic Retinopathy
9.7.1 Overview
9.7.2 Diabetic Retinopathy Market Revenue and Forecast to 2028 (US$ Million)
9.8 Diabetic Macular Edema
9.8.1 Overview
9.8.2 Diabetic Macular Edema Market Revenue and Forecast to 2028 (US$ Million)
9.9 Others
9.9.1 Overview
9.9.2 Others Market Revenue and Forecast to 2028 (US$ Million)
10. North America Ocular Drug Delivery Market Analysis – By End User
10.1 Overview
10.2 Ocular Drug Delivery Market Share, by End User, 2021 and 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Ocular Drug Delivery Market– Revenue and Forecast to 2028 (US$ Million)
10.4 Ophthalmic Clinics
10.4.1 Overview
10.4.2 Ophthalmic Clinics: Ocular Drug Delivery Market– Revenue and Forecast to 2028 (US$ Million)
10.5 Ambulatory Surgical Centers
10.5.1 Overview
10.5.2 Ambulatory Surgical Centers: Ocular Drug Delivery Market– Revenue and Forecast to 2028 (US$ Million)
11. North America Ocular Drug Delivery Market – Country Analysis
11.1 Overview
11.1.1 North America: Ocular Drug Delivery Market, by Country, 2021 & 2028 (%)
11.1.1.1 US: Ocular Drug Delivery Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.1 US: Ocular Drug Delivery Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.2 US Ocular Drug Delivery Market, by Technology – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.3 US: Ocular Drug Delivery Market, by Formulation Type – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.4 US: Ocular Drug Delivery Market, by Disease Type – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.5 US: Ocular Drug Delivery Market, by End User – Revenue and Forecast to 2028 (USD Million)
11.1.1.2 Canada: Ocular Drug Delivery Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.1 Canada: Ocular Drug Delivery Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.2 Canada Ocular Drug Delivery Market, by Technology – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.3 Canada Ocular Drug Delivery Market, by Formulation Type – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.4 Canada Ocular Drug Delivery Market, by Disease Type – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.5 Canada Ocular Drug Delivery Market, by End User – Revenue and Forecast to 2028 (USD Million)
11.1.1.3 Mexico: Ocular Drug Delivery Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.1 Mexico: Ocular Drug Delivery Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.2 Mexico Ocular Drug Delivery Market, by Technology – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.3 Mexico Ocular Drug Delivery Market, by Formulation Type – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.4 Mexico Ocular Drug Delivery Market, by Disease Type – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.5 Mexico Ocular Drug Delivery Market, by End User – Revenue and Forecast to 2028 (USD Million)
12. Impact Of COVID-19 Pandemic on North America Ocular Drug Delivery Market
12.1 Impact Assessment of COVID-19 Pandemic
13. Industry Landscape
13.1 Overview
13.2 Organic Developments
13.2.1 Overview
13.3 Inorganic Developments
13.3.1 Overview
14. Company Profiles
14.1 AbbVie Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Bausch Health Companies Inc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Ocular Therapeutix, Inc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Alimera Sciences, Inc.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Envisia Therapeutics
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 EYEGATE PHARMACEUTICALS, INC
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Clearside Biomedical, Inc.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. US Ocular Drug Delivery Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 2. US Ocular Drug Delivery Market, by Formulation Type - Revenue and Forecast to 2028 (USD Million)
Table 3. US Ocular Drug Delivery Market, by Disease Type - Revenue and Forecast to 2028 (USD Million)
Table 4. US Ocular Drug Delivery Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 5. Canada Ocular Drug Delivery Market, by Technology -Revenue and Forecast to 2028 (USD Million)
Table 6. Canada Ocular Drug Delivery Market, by Formulation Type – Revenue and Forecast to 2028 (USD Million)
Table 7. Canada Ocular Drug Delivery Market, by Disease Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Canada Ocular Drug Delivery Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 9. Mexico Ocular Drug Delivery Market, by Technology -Revenue and Forecast to 2028 (USD Million)
Table 10. Mexico Ocular Drug Delivery Market, by Formulation Type – Revenue and Forecast to 2028 (USD Million)
Table 11. Mexico Ocular Drug Delivery Market, by Disease Type – Revenue and Forecast to 2028 (USD Million)
Table 12. Mexico Ocular Drug Delivery Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 13. Organic Developments Done By Companies
Table 14. Inorganic Developments Done by Companies
Table 15. Glossary of Terms, Ocular Drug Delivery Market
LIST OF FIGURES
Figure 1. North America Ocular Drug Delivery Market Segmentation
Figure 2. North America Ocular Drug Delivery Market Segmentation, By Country
Figure 3. North America Ocular Drug Delivery Market Overview
Figure 4. Implantable Ocular Drug Delivery Systems Segment Held the Largest Share of the Technology Segment in Ocular Drug Delivery Market
Figure 5. The US to Show Significant Growth During Forecast Period
Figure 6. North America Ocular Drug Delivery Market, Industry Landscape
Figure 7. North America PEST Analysis
Figure 8. North America Ocular Drug Delivery Market Impact Analysis of Driver and Restraints
Figure 9. North America Ocular Drug Delivery Market – Revenue Forecast and Analysis – 2020- 2028
Figure 10. North America Ocular Drug Delivery Market Share by Technology 2021 & 2028 (%)
Figure 11. Implantable Ocular Drug Delivery Systems Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Particulate Drug Delivery Systems Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Nano-Particle Drug Delivery System Market Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Others Market Revenue and Forecasts to 2028 (US$ Million)
Figure 15. North America Ocular Drug Delivery Market, By Formulation Type 2021 & 2028 (%)
Figure 16. Liposomes and Nanoparticles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Solution Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Emulsion Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Suspension Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Ointment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. North America Ocular Drug Delivery Market Share by Disease Type 2021 & 2028 (%)
Figure 22. Cataract Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Dry Eye Syndrome Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. Macular Degeneration Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Glaucoma Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. Diabetic Retinopathy Market Revenue and Forecasts to 2028 (US$ Million)
Figure 27. Diabetic Macular Edema Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. Others Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. Ocular Drug Delivery Market Share, by End User, 2021 and 2028 (%)
Figure 30. Hospitals: Ocular Drug Delivery Market– Revenue and Forecast to 2028 (US$ Million)
Figure 31. Ophthalmic Clinics: Ocular Drug Delivery Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 32. Ambulatory Surgical Centers: Ocular Drug Delivery Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 33. North America: Ocular Drug Delivery Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. North America: Ocular Drug Delivery Market, by Country, 2021 & 2028 (%)
Figure 35. US: Ocular Drug Delivery Market – Revenue and Forecast to 2028 (USD Million)
Figure 36. Canada: Ocular Drug Delivery Market – Revenue and Forecast to 2028 (USD Million)
Figure 37. Mexico: Ocular Drug Delivery Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. Impact of COVID-19 Pandemic in North American Country Markets
- AbbVie Inc.
- Bausch Health Companies Inc.
- Novartis AG
- Clearside Biomedical, Inc
- Ocular Therapeutix, Inc.
- Envisia Therapeutics
- Alimera Sciences, Inc.
- EYEGATE PHARMACEUTICALS, INC
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America ocular drug delivery market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in North America ocular drug delivery market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the ocular drug delivery market as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution